載入中
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
前收盤價
US$86.01
+US$4.66 · +5.73%
盤中時間採用ET。市場資料可能有所延遲。
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
日內區間
目前US$86.01
52週區間
目前US$86.01
盤中時間採用ET。市場資料可能有所延遲。
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
日內區間
目前US$86.01
52週區間
目前US$86.01
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5.21億 USD | 3.37億 USD | 1.86億 USD | 7706.2萬 USD | 1913.8萬 USD |
| 銷貨成本 | 1.01億 USD | 8164.3萬 USD | 4703.9萬 USD | 1237.4萬 USD | 190.3萬 USD |
| 毛利 | 4.21億 USD | 2.55億 USD | 1.39億 USD | 6468.8萬 USD | 1723.5萬 USD |
| 研究與開發 | 1.86億 USD | 1.41億 USD | 1.03億 USD | 1.07億 USD | 1.31億 USD |
| 銷售、一般及管理費用 | 2.57億 USD | 2.02億 USD | 1.46億 USD | 8906.6萬 USD | 5922萬 USD |
| 營業費用 | 4.43億 USD | 3.43億 USD | 2.48億 USD | 1.96億 USD | 1.91億 USD |
| 利息收入 | 1272.7萬 USD | 1379.2萬 USD | 1373.5萬 USD | 385.7萬 USD | 36.6萬 USD |
| 利息支出 | 1438.9萬 USD | 1431.1萬 USD | 1510.5萬 USD | 1597.9萬 USD | 1759萬 USD |
| 折舊和攤銷 | 2424.4萬 USD | 2362.9萬 USD | 1082.9萬 USD | 323.8萬 USD | 97.5萬 USD |
| 營業利益 | −2213.6萬 USD | −8760.6萬 USD | −1.09億 USD | −1.31億 USD | −1.73億 USD |
| 淨利 | −2336.3萬 USD | −8794.2萬 USD | −1.63億 USD | −1.36億 USD | −8398.8萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$149.1
上漲空間 73.35%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.62億0.01%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB1.17億0.06%1853億 USD0.03%US$289.48+0.64%
iShares Russell 2000 ETFIWM1.02億0.13%787.4億 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1.01億1.03%98.74億 USD0.35%US$153.77+3.00%
Vanguard Morningstar Small-Cap Growth ETFVBK6715.9萬0.15%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF5493.16萬0.06%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO3564.94萬0.26%139.17億 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB3348.11萬0.32%108.2億 USD0.44%US$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
